ONCODESIGN SERVICES – Trademark Portfolio
Entity Type: 98
ONCODESIGN SERVICES holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include FLOREPIZOL.
18 rue Jean Mazen
F-21000 Dijon
Showing of trademarks Trademarks
Trademark Classifications
ONCODESIGN SERVICES's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does ONCODESIGN SERVICES have?
ONCODESIGN SERVICES has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered.
What trademark classes does ONCODESIGN SERVICES file in?
ONCODESIGN SERVICES files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics). Class 42 covers scientific and technological services; industrial analysis and research services.
What are ONCODESIGN SERVICES's most well-known trademarks?
ONCODESIGN SERVICES's registered trademark portfolio includes well-known marks such as FLOREPIZOL. These are among 1 currently registered trademark in the portfolio.
What is ONCODESIGN SERVICES's trademark registration success rate?
ONCODESIGN SERVICES has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.